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Abstract
Bone marrow stromal cell cultures contain multipotent cells that may have therapeutic utility for tissue restoration;
however, the identity of the cell that maintains this function remains poorly characterized. We have utilized a unique model
of murine bone marrow stroma in combination with liquid chromatography mass spectrometry to compare the nuclear,
cytoplasmic and membrane associated proteomes of multipotent (MSC) (CD105+) and non-multipotent (CD1052) stromal
cells. Among the 25 most reliably identified proteins, 10 were verified by both real-time PCR and Western Blot to be highly
enriched, in CD105+ cells and were members of distinct biological pathways and functional networks. Five of these proteins
were also identified as potentially expressed in human MSC derived from both standard and serum free human stromal
cultures. The quantitative amount of each protein identified in human stromal cells was only minimally affected by media
conditions but varied highly between bone marrow donors. This study provides further evidence of heterogeneity among
cultured bone marrow stromal cells and identifies potential candidate proteins that may prove useful for identifying and
quantifying both murine and human MSC in vitro.
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Introduction
Bone marrow contains several different cell types including the
precursors of blood, bone, fat and connective tissue. In the early
seventies, it was shown that a monolayer of adherent fibroblast-like
cells could be propagated in vitro by culturing whole bone marrow
cells for several weeks in serum containing media [1]. These cells
were found to support the growth of hematopoietic progenitors
and could differentiate into fat (adipocytes), bone (osteocytes) and
cartilage (chondrocytes) precursors both in vitro and in vivo [2,3].
Subsequently, they have been labelled as multipotent stromal cells
(MSC) or mesenchymal stem cells. More recently, MSC cultures
have been ascribed with other clinically relevant properties, such
as immune suppression [4–6], and a capacity to enhance tissue
repair [5–12]. Hence, MSC cultures have immense therapeutic
potential and are currently being tested in clinical trials for the
treatment of cartilage degeneration, myocardial infarction, di-
abetes, graft versus host disease and neurodegenerative disorders,
among others [8–10,13–17].
There have been several lines of evidence suggesting that
stromal cultures represent a heterogeneous population of cells
containing MSC. Differences have been identified in expansion
potential [18], differentiation capacity [19–22] and transcriptomic
and proteomic profiles [23,24]. In all, the body of evidence within
the literature suggests that the frequency of MSC among stromal
cultures varies based on donor, media conditions and culture age.
Despite this, markers that can discriminate MSC from non-
multipotent stroma remain elusive. The identification of such
markers may allow variation to be characterized between cultures,
providing a useful tool in both basic research and clinical settings.
Previous research in our lab has demonstrated that C57BL/6
mouse bone marrow provides a unique stromal cell culture model
that can be used to discriminate multipotent and non-multipotent
stroma based on the expression of CD105 [20,23]. In the current
work, CD105 expressing (CD105+) and non-expressing (CD1052)
stromal cells were purified from C57BL/6 stromal cultures and
analyzed by liquid chromatography mass spectrometry (LC-MS/
MS) to compare the proteome of MSC and non-multipotent
stroma. Subfractionation techniques allowed the identification of
several hundred nuclear, cytoplasmic and membrane derived
proteins that were unique to either CD105+ or CD1052 cells and
contributed to distinct canonical pathways, as demonstrated by
Ingenuity Pathway Analysis (IPA). Specific expression in CD105+
cells of 10 different proteins was verified by Western Blotting and
real time polymerase chain reaction. Screening of human stromal
cultures determined that five of the 10 proteins uniquely expressed
in murine CD105+ cells were also detectable, at varying levels, in
human bone marrow stromal cultures shown to contain MSC.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38954This work provides a proteomic signature that is specific to MSC
and a list of potential candidate in vitro markers for these
therapeutically relevant cells.
Materials and Methods
Bone Marrow Stromal Cultures
This study was approved by the Health Canada Animal Care
Committee and all housing and treatment of animals was carried
out according to the approved protocol. Murine stromal cultures
were initiated as previously described [23]. Briefly, bone marrow
(BM) was flushed from femur, tibia and iliac crest of 8–12 week old
female C57BL/6J mice (Jackson Laboratories, Bar Harbour, ME)
and was seeded at 4.0610
6 white blood cells (WBC) per millilitre
(mL) of Mesencult MSC Basal Medium containing murine MSC
stimulatory supplements, referred to here-in as Mesencult
Complete Medium (StemCell Technologies, Vancouver, BC).
After 14 to 21 days, cells were harvested with Trypsin-EDTA
(StemCell Technologies) and endothelial and hematopoietic cells
were removed using 2 rounds of immunomagnetic purification
with a custom EasySep cocktail (StemCell Technologies). Human
bone marrow was purchased from Lonza Walkersville (Lonza,
Walkersville, MD), an establishment registered under the FDA for
the processing of human cells, tissue and cellular and tissue based
products in accordance with the US Code of Federal Regulations
(21 CFR Par 1271). Human tissues provided by Lonza are
obtained from various tissue suppliers and recovery agencies
according to Institutional Review Board approved protocols and
informed consent that allow the use of obtained tissues for general
research purposes. Human stromal cell cultures were initiated
either by plating 1610
6 cells per mL in low glucose Dulbecco’s
Modified Eagles Medium (DMEM) (Invitrogen/GIBCO BRL,
Burlington, ON) with 15% Fetal Bovine Serum (FBS) qualified for
human MSC (HyClone-Thermo-Fisher, Nepean, ON) [Serum
Containing (SC) media] or in Serum and Animal Component Free
media provided by Stem Cell Technologies, herein referred to as
Serum Free (SF) media.
Flow Cytometry and Cell Sorting
Stromal cells were trypsinized, filtered through a 70 mm cell
strainer (BD Bioscience, San Diego, CA) and resuspended in PBS/
2%FBS at 1610
3 cells/mL. Cells were simultaneously stained with
fluorochrome-conjugated monoclonal antibodies (mAb) to human
CD105-Allophycocyanin (APC) (SN6); CD34-Phycoerythrin-Cy7
(PE-Cy7) (4H11); CD45-Fluorescein Iso-Thiocyanate (FITC)
(H130); CD90-PE-Cy5.5 (5E10); Mdr-1-PE (U1C2) (eBioscience,
San Diego, CA) and CD73-PE (AD2) (BD Bioscience). For
Fluorescence Activated Cell Sorting (FACS), murine stromal cells
were stained with anti-mouse CD105-PE (MJ7/18) (eBioscience).
Flow cytometric analysis was completed on a minimum of 30 000
viable cells using an LSR II instrument (BD Bioscience) and the
data were analyzed using FLOWJO
TM software (TreeStar Inc.,
Ashland, OR). FACS was completed on a MoFlo
TM instrument
(Beckman Coulter, Mississauga, ON).
Multipotent Differentiation Cultures
Differentiation of stromal cells into adipocytes, osteocytes and
chondrocytes was completed using the Human MSC Functional
Identification Kit from R&D Systems (R&D Systems, Minneapo-
lis, MN). Briefly, to initiate adipocyte and osteocyte formation,
stromal cells were cultured in either SC or SF media in 24-well
plates using 2.1610
4 cells/cm
2 and 4.2610
3 cells/cm
2 cells,
respectively. Media containing supplements to allow the differen-
tiation of adipocytes or osteocytes was added when cells reached
100% or 50% confluence, respectively. Media was changed every
3–4 days over a 10–28 day period. For chondrogenic differenti-
ation, 1.25610
5 of cultured stromal cells were grown in 15 mL
polypropylene conical tubes with DMEM/F12 media containing
chondrogenic supplements. Media was changed every 3 days for
17–21 days. Adherent cells and pellets were fixed in 4%
paraformaldehyde and either stained directly (adipocytes/osteo-
cytes) or cryosectioned prior to staining (chondrocytes). Sections of
8–10 mm were placed on charged glass slides (VWR, Mississauga,
ON). For chemical detection of adipocytes, fixed cells were treated
with 60% isopropanol for 10 minutes and were stained with Oil
Red O for 5 minutes (Sigma-Aldrich, St. Louis, MO). Osteocyte
identification was accomplished by staining fixed cells with 0.2%
Alizarin Red Stain at pH 6.36–6.4 (Baker) for 60 minutes. The
cryosectioned pellets acquired from chondrocyte differentiation
cultures were stained in Alcian blue stain, pH 1.0, for 15 minutes.
Stained cells were washed thoroughly with distilled water and
visualized under a light microscope (Zeiss, Toronto, ON) equipped
with an Axiom camera.
Cellular Subfractionation and Protein Purification
For cellular subfractionation, 5610
7 CD105+ and CD1052
cells were harvested using enzyme-free cell dissociation buffer
(Invitrogen) and centrifuged at 700 g for 5 minutes at +4uC. The
cells were washed and resuspended in 1 ml of homogenization
buffer mix from BioVision’s Membrane Protein Extraction Kit
(BioVision, San Francisco, CA). The cells were lysed in an ice cold
Dounce homogenizer and centrifuged at 700 g for 10 minutes at
+4uC. Pellets consisting of intact nuclei were kept for nuclear
extraction while supernatants were used to purify cytosolic and
membrane protein fractions according to the manufacturer’s
instructions (BioVision). The nuclear pellet was dissolved in 250 ml
ice-cold NEB mix from BioVision’s Nuclear/Cytosol Fraction-
ation Kit, incubated on ice for 10 minutes and vortexed for
15 seconds. The nuclear proteins were collected by centrifugation
at 16,000 g for 10 minutes. Proteins from each subfraction were
quantified using a BCA Protein Assay Kit and 200 mg of each was
utilized for mass spectrometry.
LC MS/MS and Proteomic Data Analysis
Proteins were digested by sequencing-grade trypsin in 25 mM
NH4HCO3 at 37uC overnight, following reduction with 10 mM
dithiothreitol, alkylation with 55 mM iodoacetamide and sub-
sequently dialysis to remove these chemicals. Further separation of
the protein extracts was carried out on 10% SDS-PAGE gel (Bio-
Rad Laboratories, CA), and the Coomassie-stained bands were
excised and digested in-gel using a standard method described
elsewhere [23].
Online LC MS/MS analysis was performed on a Nano-Acquity
ultra-performance liquid chromatography system (UPLC, Waters,
Milford, MA) coupled to a 7-tesla hybrid linear ion trap Fourier
transform ion cyclotron resonance mass spectrometer (LTQ-FT
ICR, Thermo Fisher, San Jose, CA). The peptides were trapped
by a RP Symmetry C18 column (180 mm i.d.620 mm length,
5 mm; Waters) at 5 mL/min, and subsequently separated on a C18
analytical column (100 mm i.d.6100 mm, 1.7 mm, BEH 130;
Waters) at 500 nl/min. Peptides were eluted using mobile phases
consisting of solvent A (0.1% formic acid) and solvent B (97.9%
acetonitrile/0.1% formic acid/2% water). NanoUPLC separation
was achieved by a linear gradient from 5% to 45%, and then 85%
of solvent B at a duration time of either 90-min for the tryptic
digest of protein gel isolates, or 4 hours for the digest of proteins
isolated directly from subcellular fractions.
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mode following a full FT-MS survey scan over a mass range of m/
z 300–2000. Protein identification was achieved by searching
against SwissProt-UniProt (updated on December 1
st, 2011,
533049 sequences) and NCBI (16338050 sequences) decoy
databases using an in-house Mascot Server (version 2.3.2, Matrix
Science, London, UK) with a false discovery rate less than 5%.
The Mascot search parameter settings allowed trypsin digestion
for maximum 2 missed cleavage sites, and carbamidomethylation
of cysteine as a fixed modification. Deamidation of Asn and Gln,
oxidation of Met, and N-terminal pyroglutamation of Gln were
considered as variable modifications. Mass tolerances were set up
to 10ppm for the FT MS ions, and 1 Da for the ion trap MS/MS
fragment ions. The results were then combined and analyzed by
Scaffold (version 3.1.4.1, Proteome software Inc. Portland, OR) to
allow side-by-side comparison of proteins identified in subcelluar
fractions. For Scaffold analysis, parameters were based on the
identification of at least 1 peptide with an ion score greater than
20. This resulted in 77079 spectra with a 0.1% FDR that were
assigned to 1254 proteins with an FDR of 0.8%.
Real Time Quantitative RT-PCR
Total RNA was purified from 2610
6 CD105+ and CD1052
cells using the RNeasy Plus Mini Kit (Qiagen, Toronto, ON)
according to the manufacturer’s protocol. Extracts were treated
with DNase (Applied Biosystems, Streetsville, ON) and quantified
using a Nanodrop 1000 spectrophotometer (Fisher Scientific). One
microgram RNA was used to synthesize cDNA using Superscript
III First Strand Synthesis System for RT-PCR (Invitrogen/Gibco).
Real time PCR was completed using the Power SYBR Green
PCR Master Mix and the 7500 FAST Real-Time PCR System
(Applied Biosystems). PCR results were normalized to actin
expression and the delta-delta CT method was used for de-
termining fold changes. For a complete list of utilized primers see
Table S1.
Western Blotting
Whole cell protein extracts (5–40 ug) were loaded onto 8–12%
acrylamide gels, separated and transferred to PVDF membranes
(Millipore, Etobicoke, ON) for 1 hour. After overnight blocking at
4uC with 1% Western Blocking Reagent (Roche, Mississauga, ON)
in TBS + 0.1% Tween 20, blots were incubated with primary
antibodies (Table S2) as per manufacturer’s instructions. Primary
antibody was visualized using either anti-rabbit or anti-mouse IgG
Horseradish Peroxidase (HRP) conjugated antibody (1:2000) (GE
Healthcare, Mississauga, ON), anti-Goat IgG-HRP (1:10 000)
(Santa Cruz Biotechnology) or anti-Sheep IgG HRP (1:200 000)
(Jackson Labs) for 1 hour at room temperature. After washing, the
presence of antibody was detected using SuperSignal West Dura
Extended Duration Substrate. Protein loading was normalized
using anti-actin (1:50 000) or anti-vinculin (1:2000) (Sigma)
Results
Purification of murine stromal cells based on CD105
expression allows proteomic comparison of MSC and
non-multipotent stroma
The identification of distinct populations of multipotent and
non-multipotent stromal cells in C57BL/6 mouse bone marrow
cultures that could be distinguished based on CD105 expression
(20) provided a unique opportunity to identify specific markers of
MSC. As a first step in accomplishing this goal, we set out to utilize
the C57BL/6 stromal culture model to generate a list of proteins
that are specifically expressed in CD105+ stromal cells. As mass
spectrometry has proven a reliable method for analyzing cellular
proteins [23,25,26], we utilized LC MS/MS to compare the
proteome of FACS purified CD105+ and CD1052 stroma. In
three replicate experiments, stromal cell populations were isolated
to a purity of $95% and tested in differentiation culture assays to
ensure that the multipotent potential of CD105+ and CD1052
fractions was maintained (Figure 1A). As observed in our previous
studies [20], only CD105+ cells demonstrated the capacity to
differentiate into adipocytes, osteocytes and chondrocytes.
To increase the depth of coverage for LC MS/MS analysis, and
reduce masking from high abundance proteins, FACS purified
CD105+ and CD1052 cells were subfractionated into nuclear,
cytosolic and membrane components (Figure 1B). Proteins were
isolated from each of these subfractions individually and nuclear
and cytosolic proteins were analyzed by LC MS/MS directly in
each of the three replicate experiments. CD105+ and CD1052
cell derived membrane proteins were divided in half and further
purified to remove detergents using one of two methods: PAGE
separation and Filter Assisted Sample Preparation (FASP) [27].
While more proteins were identified during LC MS/MS analysis
of PAGE separated membrane proteins, some proteins could only
be consistently identified by FASP (data not shown). Thus, the
results obtained from the purification of membrane proteins using
both methods were combined to determine membrane proteomic
profiles for CD105+ and CD1052 stroma.
A list of proteins expressed by CD105+ or CD1052 cells was
generated from datasets obtained by LC MS/MS analyses of
nuclear, cytoplasmic and membrane subfractions through MAS-
COT using P values of .0.05 and a 5% false discovery rate.
Peptides were assigned using both the mouse NCBI and SwissProt-
UniProt databases and those with MASCOT scores less than 20
were discarded. Lists were further refined using Scaffold analysis to
compare the nuclear, cytosolic and membrane proteins identified
in replicate experiments; any proteins that were not identified in
each experiment were omitted. Proteins determined from nuclear,
cytosolic and membrane subfractions were then compiled to
generate a list of 2209 and 2094 proteins expressed in CD105+
and CD1052 cells, respectively. A database comparison of these
lists found 1509 proteins (70%) common to both cell types
(Figure 1B). Proteins were also identified that were characteristic to
either CD105+ or CD1052 cell extracts. Specifically, 700 proteins
were detected only in CD105+ cells, while 585 were detected in
CD1052 cells, in each of the three biological replicate cultures
analyzed. Thus, through extensive protein fractionation, LC MS/
MS analysis and data comparison techniques, we have identified
a list of proteins that may be expressed at different levels in murine
MSC and non-multipotent stroma.
Proteins characteristic to either CD105+ or CD1052
stroma contribute to divergent canonical pathways
Currently, little is known about the biological pathways that are
activated in cultured stromal cells. To determine whether proteins
that were identified as common or unique to MSC and non-
multipotent stroma were enriched within specific canonical
pathways, the sets of proteins identified by LC MS/MS analysis
of CD105+ and CD1052 cells were subjected to Ingenuity
Pathway Analysis (IPA). The top four most significant canonical
pathways identified from the common and unique protein lists are
shown in Figure 2 (p#0.05). Cytoskeletal, cell maintenance and
integrin signalling pathways were identified as common to both
cell types. IPA determined that the LC MS/MS generated
CD105+ and CD1052 unique protein lists were enriched for
proteins involved in distinct canonical pathways. Specifically,
proteins identified among CD1052 cell extracts were involved in
A Protein Signature for Multipotent Stromal Cells
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38954Figure 1. Purification of murine stroma based on CD105 expression allows the identification of proteins that are unique to
multipotent and non-multipotent stroma. (A) CD105 expression demarcates MSC and non-multipotent stromal cells in C57BL/6 bone marrow
derived cultures. CD1052 (R1) and CD105+ (R2) stromal cells were purified by FACS and cultured under conditions that support adipocyte, osteocyte
and chondrocyte differentiation. (n=3) (B) Schematic of method used to compare the proteome of multipotent and non-multipotent stroma.
CD105+ and CD1052 stroma were isolated from 3 separate cultures. Proteins were isolated from the nuclear, cytoplasmic and membrane fractions
and analyzed by LC MS/MS. Proteins identified in each of the 3 experiments were pooled to generate data sets representative of MSC (blue) or non-
multipotent stroma (yellow). Data from the two populations was generated from both the NLM and Swiss Prot data bases and compared using
Microsoft Access
TM to generate lists of both unique and common proteins.
doi:10.1371/journal.pone.0038954.g001
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ways while the top canonical pathways among proteins charac-
terized in CD105+ cells were axonal guidance signalling, DNA
methylation and transcriptional repression signalling. The gene
symbols corresponding to each of the proteins associated with
these four canonical pathways are listed in Table 1. Overall, IPA
provides evidence that proteins identified through LC MS/MS
analysis of CD105+ and CD1052 cells comprise distinct protein
sets representing two functionally distinct stromal cell populations.
Real-time RT-PCR and Western Blot analysis confirm LC
MS/MS identified proteins as candidate markers of
murine MSC
In order to further assess the list of proteins identified in
CD105+ cells as potential markers of MSC, we set out to
quantitatively compare their expression at the mRNA and protein
level. To narrow the focus of the study to a more manageable
number of proteins, we chose to focus on the top 25 CD105+ cell
specific proteins as ranked by Scaffold analysis. These proteins are
listed in Table 2, in the order of their Scaffold ranking, along with
the subcellular fraction in which they were associated. The
number of unique peptides identified and percent protein coverage
Figure 2. Proteins uniquely expressed in multipotent and non-multipotent stroma are involved in distinct canonical pathways. Lists
of proteins that were either common or unique to CD105+ and CD1052 stroma were analyzed using Ingenuity Pathway Analysis software. The
orange line signifies the cut-off P value used to assess the significance of each pathway. The top 4 canonical pathways identified in each group are
reported.
doi:10.1371/journal.pone.0038954.g002
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sequences of peptides identified by LC MS/MS and used for
protein identification, in this representative experiment, are shown
in Table S3 along with their ion scores. Among the 25 proteins
listed, 10 proteins were chosen for quantitative verification based
on the commercial availability of reliable antibodies. These
included the membrane associated proteins CD248, Thrombos-
pondin-1 (Thbs1), Neuropilin-1 (Nrp1) and Multi-drug Resistant
Protein-1 (Mdr-1; P-glycoprotein) as well as nuclear and cytosolic
proteins Prostacyclin synthase (Ptgis), Adenosine kinase (Adk),
Growth arrest specific protein-2 (Gas2), Epoxide hydrolase-1
(Ephx1), Fibulin-2 and High mobility group box-1 (Hmgb1). In
addition, based on their known roles in cell signalling, we chose to
investigate the expression levels of two additional membrane
proteins that were identified with lower Scaffold ranks: Oncostatin
M receptor-1-beta (Osmr1) and Ephrin receptor B3 (EphB3).
To compare the gene expression levels of these proteins, mRNA
was extracted from a portion of the same CD105+ and CD1052
cells used for LC MS/MS analysis. Gene expression levels for
candidate MSC markers were determined by real-time RT PCR
and normalized with actin expression. The gene expression levels
for 3 proteins that were identified as common between CD105+
and CD1052 cells (Trophoblast glycoprotein (Tpbg), Frizzled-2
(Fzd2) and High mobility group AT-hook 1 (Hmga1)) were utilized
as controls for relative quantification. As expected, less than 2-fold
differences in mRNA transcript were detected for Tpbg and
Hmga1 in CD105+ and CD1052 cell types; however, Fzd2
transcript was upregulated 2.560.3 fold in CD105+ cells
(Figure 3A). Each of the 12 candidate MSC markers tested were
detected in CD105+ cells at levels greater than 2 fold compared to
CD1052 cells. Of particular interest were the Ptgis mRNA which
was exclusively identified in CD105+ cells, as well as Gas2 and
CD248 that were expressed at 58613 and 8.562.3 fold greater
levels compared to CD1052 cells.
Previous work from our group has demonstrated that mRNA
expression levels in stromal cells, as detected by real-time RT
PCR, do not always correlate with the amount of protein present
in the cell [23]. To this end, the 12 candidate markers identified by
LC MS/MS were further validated by Western Blotting. Whole
cell protein extracts isolated from CD105+ and CD1052 cells
were confirmed to contain equivalent amounts of CD147, Tpbg
and Actin (Figure 3B). As well, Western Blot analysis of Fzd2
expression demonstrated that while mRNA transcripts were
upregulated in CD105+ cells, the amount of protein detected in
both cell types was the same. A clear discrepancy between gene
expression profiles and Western Blot analysis was also determined
for Osmr1 and EphB3 which showed little to no quantitative
differences at the protein level despite a 3.260.6 and 4.961.5 fold
higher level of mRNA expression. These results re-iterate the
importance of utilizing both protein and gene expression methods
of quantification when investigating biological systems.
Of the membrane proteins detected only in CD105+ cell
extracts by LC MS/MS, CD248 and Thbs1 were confirmed as
highly upregulated by Western Blotting while Nrp1 and Mdr1
showed a more modest level of enrichment. Western Blot analysis
of nuclear and cytosolic proteins that were characteristic of
CD105+ cells showed clear differences compared to CD1052
stroma for each of the 6 candidate markers. The largest differences
in expression, were found in Ptgis, Gas2, Ephx1 proteins where
distinct bands corresponding to these proteins were detected in
CD105+ cell extracts, but notably absent in extracts derived from
CD1052 cells. These results were confirmed over three different
protein concentrations (data not shown). Hmgb1, Fbln2 and Adk
proteins were also enriched in CD105+ cells, although to a lower
extent compared to the other candidate MSC markers. Overall,
real-time RT-PCR and Western Blot analysis have confirmed 10
candidate markers for the discrimination of MSC and non-
multipotent stroma in vitro. These candidate markers include both
membrane (CD248, Thbs1, Nrp1 and Mdr1) and nuclear or
cytosolic (Ptgis, Gas2, Ephx1, Hmgb1, Adk and Fbln2) associated
proteins.
Candidate markers of murine MSC are detectable in
human bone marrow stromal cultures containing MSC
To determine the potential utility of our identified markers of
murine MSC towards the identification of human MSC, we
generated human bone marrow stromal cultures from four
separate donors to use for marker validation. To determine the
effect of growth conditions on protein expression, cultures were
generated using both serum containing (SC) and serum free (SF)
media. Early passage adherent cells were analyzed for stromal cell
purity by flow cytometry according to criteria described by the
International Society of Cell Therapy [28]. As demonstrated in
Figure 4A, all cell lines lacked cells expressing CD45, demon-
strating that they were free of hematopoietic cell contamination.
Cultures were also found to be free of cells expressing CD34 (data
not shown). Stromal cell purity was further demonstrated in both
SC and SF cultures by the detection of CD105, CD73 and CD90
on the surface of greater than 90% of all cells.
To determine the presence of MSC, an aliquot of cells from
each culture was plated in media that promotes the differentiation
of adipocyte, osteocyte or chondrocyte precursors (Figure 4A).
Regardless of the presence of serum, cultures derived from each of
the 4 donors tested were found to contain MSC as demonstrated
Table 1. List of proteins identified by LC MS/MS in CD105+ cells that participate in specific canonical pathways as determined by
IPA analysis.
Axonal Guidance Signaling ABLIM3; ADAM29; AKT1; AKT2; CDK5; CRK; EPHB6; GLI2PAK1; GNA12; GNAL; GNAO1; GNAT2;
MYL6B; NGEF; NRP1; SRGAP1; PAK2; PRKCA; PRKACB; PRKAR1A; PRKAR2A; PLXNA1; RAC3;
RGS3; ROBO1; ROCK1; RRAS2; TUBA1C; TUBA4A
DNA Methylation and Transcriptional Repression Signaling CHD3; CHD4; MTA1; RBBP7; MTA2; ARID4B
Amyloid Processing AKT1; AKT2; CAPN6; CDK5; CSNK2A2; CSNK2B; PRKACB; PRKAR2A; PRKAR1A
Molecular Mechanisms of Cancer AKT1; AKT2; ARHGEF1; CASP6; CDK2; CDK4; CDK6; CRK; DAXX; FOS; GNA12; GNAO1; GNAL;
GNAT2; PAK1; PAK2; PRKACB; PRKAR1A; PRKAR2A; PRKCA; RAC3 RAPGEF1; RASGRF2; RHOC;
RHOG; RRAS2
Proteins detected only in CD105+ cell extracts were analyzed by IPA software to determine their potential role in canonical signalling pathways. Proteins identified to
participate in the top four canonical pathways are listed in alphabetical order.
doi:10.1371/journal.pone.0038954.t001
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(adipocytes), Alizarin Red (osteocytes) and Alcian Blue (chondro-
cytes). Together, flow cytometric and multipotent differentiation
assays demonstrate the successful generation of human bone
marrow stromal cultures containing MSC using both SC and SF
media.
To analyze the relative expression levels of candidate MSC
markers in human bone marrow derived stromal cultures, we
utilized Western Blot. Whole cell proteins were extracted from
early passage cultures shown above to have multipotent function.
Antibodies specific to the human proteins corresponding to those
identified in murine stroma, were used to probe equal amounts of
whole protein lysate derived from each of the four human stromal
cultures (Figure 4B). To control for errors in loading, individual
blots were stripped and reprobed using antibodies specific to either
actin or vinculin. Of the candidate marker proteins analyzed,
Ptgis, Ephx1, Fbln2, Mdr1 and Thbs1 were not detected in all
human stromal cultures containing MSC; suggesting that they
may not be markers of human MSC. Interestingly, the detection of
Ephx1 (hBM1SC, hBM4SF) and Ptgis (hBM1SC, hBM2SC,
hBM4SF) seemed to vary by donor. In contrast, the expression of
Thbs1 and EphB3 proteins varied by condition, being detected at
much higher levels in cultures propagated with serum. The Mdr1
protein, which was highly enriched in murine CD105+ cells, was
not detectable in human stromal cultures containing MSC. A lack
of Mdr-1 expression on human stroma was confirmed by flow
cytometry (data not shown).
Western blot analysis of human stromal cell lysates did identify
five proteins; Adk; Gas2; Hmgb1; CD248; and Nrp1 in all MSC
containing stromal cultures regardless of donor origin or culture
conditions. CD248 was the only protein that was detected at
similar quantities in all cultures tested. The pattern of expression
for intracellular proteins, Adk, Gas2 and Hmgb1, was similar and
seemed to be dependent upon donor, with higher levels identified
in hBM1SC and hBM3SF. By contrast, the membrane associated
protein Nrp1 was detected at similar amounts in hBM1SC and
hBM4SF but showed reduced expression in hBM2SC and
hBM3SF. Interestingly, both modified (130 kDa) and unmodified
(120 kDa) forms of Nrp1 were detected in each of the cell culture
derived lysates. The ratio of modified to unmodified protein also
varied by donor and did not correlate directly with the overall
amount of Nrp1 protein detected in each lysate. Stromal cells
derived from hBM2SC did not express unmodified Nrp1 at levels
detectable by Western Blot. These data suggest that variable
amounts of activated and inactivated Nrp1 are present in stromal
cultures derived from different donors. Overall, our work
Table 2. List of 25 CD105+ cell unique proteins with the highest Scaffold ranking.
Protein name Abbr. Access. number
Unique peptides (coverage) Nuclear Cytosol
Membrane
High mobility group box 1 Hmgb1 P63158 19(54%) 0 0
Chondroitin sulfate proteoglycan 4 Cspg4 Q8VHY0 0 0 63(34%)
Type VI collagen alpha 3 Col6a3 D3YWD1 0 0 38(35%)
Prostacyclin synthase Ptgis O35074 7(20%) 2(7%) 19(47%)
Serum deprivation-response protein Sdpr Q63918 7(22%) 5(18%) 0
FK506 binding protein 3 Fkbp3 Q3UBU9 7(33%) 0 0
Adenosine kinase Adk P55264 9(36%) 9(36%) 0
Biglycan Bgn P28653 0 0 11(35%)
Endosialin-CD248 CD248 Q91V98 0 0 3(3%)
Collagen alpha-1(VI) chain Col6a1 Q04857 0 0 18(20%)
Growth arrest-specific protein 2 Gas2 P11862 0 0 16(64%)
Topoisomerase (DNA) II beta Top2b Q64511 9(7%) 0 0
Flightless I homolog Flii Q9JJ28 0 5(5%) 0
Collagen alpha-2(VI) chain Col6a2 Q02788 0 0 11(13%)
Yap1 protein Yap1 P46938 6(24%) 0 0
Epoxide hydrolase 1 Ephx1 Q9D379 6(14%) 0 28(56%)
Isoform 6 of Dynamin-1 Dnm1 P39053 0 0 27(36%)
Thrombospondin 1 Thbs1 P35441 9(10%) 0 4(3%)
Peptidyl-prolyl cis-trans isomerase FKBP4 Fkbp4 P30416 0 5 6(14%)
Neuropilin-1 Nrp1 P97333 0 0 12(18%)
Treacle Protein Tcof O08784 5(5%) 0 0
Y-box-binding protein 2 Ybox2 Q9Z2C8 5(12%) 0 0
Multidrug resistance protein 1 Mdr1 P06795 0 0 6(8%)
Fibulin 2 Fbln2 P37889 3(4%) 3(4%) 0
Matrix metalloproteinase-14 Mmp14 P53690 0 0 4(6%)
Proteins identified by LC MS/MS analysis of the nuclear, cytoplasmic and membrane subfractions of CD105+ cells were compared to those identified from CD1052 cells
in each of 3 replicate experiments. Unique proteins were sorted according to their Scaffold rank scores. The 25 highest ranking proteins are listed along with the
number of unique peptides identified and percentage of protein coverage from a representative experiment (n=3). Also listed are the subcellular fractions from which
each protein was consistently isolated in each of the three experiments.
doi:10.1371/journal.pone.0038954.t002
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expression may represent a novel signature of human bone
marrow derived MSC in vitro.
Discussion
With the vast number of recent studies providing pre-clinical
evidence for the potential therapeutic utility of stromal cell
cultures, it has become increasingly important to address their
heterogeneity as a measure of both safety and effectiveness in
a clinical setting. This fact is underscored by the variable results
that have been collected from clinical studies on graft versus host
disease by different groups [14,17]. The identification of pro-
spective markers for stromal cells based on their therapeutic
function could have immense benefit in both clinical and non-
clinical settings. To further this goal, a non-quantitative LC MS/
MS approach was utilized in an attempt to identify proteins
expressed in MSC, that were not detectable in non-multipotent
murine stroma. Several proteins were differentially detected in
multipotent or non-multipotent murine stromal cells that could be
further tested as candidate markers of human MSC. One measure
of the accuracy of our data was provided by the identification of
proteins previously associated with both human and murine
stromal cells, such as CD248 (Endosialin) and Nrp1. CD248 is
a membrane bound glycoprotein that is a known in vivo marker of
stromal cells that support lymphoid development and splenic
repair [29,30]. In addition, cultured human stromal cells have
been shown to express CD248 using both flow cytometric and
real-time RT PCR analysis [30]. Our identification of CD248
expression in MSC containing cultures not only provides an
indication of the accuracy of our method for determining potential
markers of MSC, but suggests a more specific role for this protein
in regulating stromal cell multipotency.
Proteins detected exclusively in murine MSC and non-multi-
potent stroma by LC MS/MS were found to group into distinct
canonical pathways by IPA analysis. Interestingly, three of the four
MSC specific canonical pathways included proteins that have been
previously implicated in the proliferation and differentiation of
stem cells. These include cyclin dependent kinases (CDK2 and 4)
and protein kinase family members (AKT1, PRKACB) of which
reduced expression has been shown to promote differentiation in
MSC and other somatic stem cells [31–33]. These data provide
further support for the reliability of our approach. As many of the
proteins identified in this study have yet to be associated with stem
Figure 3. Real-time PCR and Western Blot analysis validate potential markers of MSC that are associated with distinct functional
networks. The expression levels of 16 proteins that were identified as either common to all stroma, or unique to CD105+ cells, were chosen for
verification based on the availability of reliable antibodies. (A) Comparison of gene expression levels in CD105+ and CD1052 cells. An aliquot of the
CD105+ and CD1052 cells used for LC MS/MS was utilized for mRNA isolation and converted to cDNA for real-time RT PCR comparison of gene
expression (n=3). Results were normalized to GAPDH and fold change in gene expression was determined in comparison to levels detected in
CD1052 cells. (B) Western Blot analysis of protein expression levels in CD105+ and CD1052 cells. In three separate experiments, whole proteins
extracts were obtained from CD105+ and CD1052 cells grown to the identical passage as used for LC-MS/MS experiments. Equivalent amounts of
each protein extract were probed by Western Blot for the presence of common or unique proteins. Analysis of either actin or vinculin expression was
completed on each blot to act as a loading control.
doi:10.1371/journal.pone.0038954.g003
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work may include novel regulators of MSC function.
The current manuscript describes twenty-five different proteins
that were uniquely identified in murine MSC enriched cells by LC
MS/MS, ten of which were verified using real-time RT PCR and
Western Blot. Of these, only five were further shown to be
expressed by human stromal cultures containing MSC. This
finding may be indicative of the distinct differences that have been
previously reported between human and murine derived MSC.
Such differences include changes in surface phenotype, growth
rate, and the frequency of transformation events [34,35]. In
particular, our finding that the Mdr1 protein, an ABC transporter
efflux pump responsible for the side population (SP) phenotype of
several different types of somatic stem cells [36–38], was expressed
Figure 4. Standard and serum free human stromal cultures containing MSC, harbour cells that express candidate markers of
murine MSC at varying quantities. Human bone marrow derived stromal cultures were initiated from 4 different donors in either serum
containing (SC) or serum free (SF) conditions. (A) Human stromal cultures containing MSC can be derived in the either SC or SF media. Cultures were
analyzed after first passage by both flow cytometry and in multipotent differentiation assays according to ISCT established criteria for MSC. Gates
established based on unstained controls were used to compare the frequency of CD105, CD73, CD90 and CD45 expressing cells. Evidence of
adipocyte, osteocyte and chondrocyte differentiation from each culture was verified by Oil Red O, Alizarin Red and Alcian Blue staining respectively
(n=4). (B) Extracts from human MSC containing stromal cultures express murine MSC specific proteins at frequencies that vary according to both
donor and culture condition. An equal quantity of whole cell protein extracts was analyzed by Western Blotting for the presence of murine MSC
associated proteins. The molecular weight of each protein is shown at the right of each blot. Nrp1 antibody recognized both modified (130 kDa) and
unmodified (120 kDa) forms. Individual blots were analyzed for either actin or vinculin as a control for protein loading.
doi:10.1371/journal.pone.0038954.g004
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studies. Specifically, MSC have been found to exist in murine bone
marrow cells with an SP phenotype but not in human bone
marrow SP cells [35]. Nonetheless, it is important to note that
despite some inherent differences, murine stromal cells may still
provide an appropriate model for studying MSC as differences in
the differentiation potential, immune suppressive capacity and
tissue restorative function of murine and human MSC have yet to
be discovered. In all, the markers identified here could provide
a useful means for further purification of murine or human MSC
which may allow more accurate study of the therapeutic utility of
stromal cell cultures.
An additional protein reported in our study to be exclusively
detected in murine CD105+ is Ephx1. Ephx1 has been previously
associated with adipogenesis in MSC through the activation of
cryoprotective lipid mediators [39]. Thus, the varied expression of
Ephx1 in human stromal cultures identified here may indicate that
this protein is an early marker of adipocyte committed progenitors
within cultured stroma. In support of this, our previous work
demonstrated that clones of adipocyte restricted progenitors exist
within the CD105+ fraction of murine stromal cultures, while such
clones could not be detected in CD1052 fractions [20]. Thus, we
suggest that the identification of Ephx1 expressing cells in human
stromal cultures, may be an indication of increased numbers of
cells that have committed to the adipocyte lineage.
Nrp1 is a membrane associated glycoprotein that functions as
a co-receptor for vascular endothelial growth factors and plexins
[40] with a primary function in vascular and neural development.
Ball and others demonstrated that human stromal cells express
Nrp1 which co-localizes with platelet derived growth factor
(PDGF) receptors, initiating cell migration and proliferation in
response to PDGFs and VEGF-A [41]. This finding correlates
with reports from several other groups that have demonstrated
PDGF-BB to be an important factor in the maintenance and
expansion of MSC in culture [42–44]. The association of Nrp1
expression with both human and murine MSC in our study
supports this body of work. In addition, identification of greater
quantities of Nrp1 in a murine stromal population enriched for
multipotent function suggests that signalling through this receptor
may be enhanced in MSC. Of particular interest in human
stromal cells are the differences uncovered in both the overall
quantity of Nrp1 and the relative amounts of modified and
unmodified protein between bone marrow donors. The signifi-
cance of this requires further investigation but adds to the current
body of evidence demonstrating heterogeneity between stromal
cultures derived from different donors. Overall, our data support
previous work demonstrating an important role for Nrp1 and
PDGF signalling in MSC and suggest that differences in Nrp1
expression levels may provide a suitable marker for discriminating
MSC from non-multipotent stroma.
The work presented here represents the first association of
elevated Hmgb1 expression levels in stromal cells with multipotent
function. Hmgb1 was originally identified as a nuclear protein that
regulates gene transcription through nucleosome binding and
stabilisation [45–47]. Since that time it has been further
demonstrated to function as a cytokine with the capacity to
regulate inflammatory immune responses [48–50] and participate
in cardiac repair [51,52], functions that have also been ascribed to
MSC. Thus, understanding the role of enhanced Hmgb1
expression in MSC may provide further insights into their clinical
utility. Of further interest are the findings that stromal cells express
the putative receptors of Hmgb1, Toll-like receptor-2 and 4
proteins [53,54], and are capable of migration and proliferation in
vitro in response to Hmgb1 [55,56]. These findings, together with
our work, suggest the potential for autocrine signalling mechan-
isms in MSC through Hmgb1. Overall, our work suggests Hmgb1
as an important candidate as both a distinguishing marker and
potential regulator of bone marrow derived MSC function.
Several different culture conditions have been reported to allow
the maintenance and expansion of human stromal cells [44,57–
60]. While standard conditions contain 10 to 15 percent FBS, the
potential clinical utility of stromal cells has pushed the de-
velopment of serum and animal component-free culture media.
Compared to standard media conditions, human stromal cells
grown in serum free media have been shown to have comparable
multipotent capacity but expand more rapidly and have a slightly
increased capacity to suppress T-cell activation [58]. Our study
provides evidence that the removal of serum has minimal effects
on the protein expression levels, at least for the ten potential MSC
markers evaluated. Of these, only Thbs1 was found to be
differentially expressed in serum free cultures compared to cells
grown in standard conditions. In fact, the majority of differences
identified between cell lines were identified between donors. While
the number of samples tested in our study is not sufficient to make
definitive conclusions regarding donor variation, the differences
found in protein expression levels between samples emphasize the
degree of heterogeneity present in human bone marrow derived
stromal cell cultures.
Overall, we have identified a list of 25 proteins that provide
a candidate signature for MSC within stromal cell cultures. Five
proteins specifically (Adk, Gas2, Hmgb1, Nrp1 and CD248) were
verified to be expressed at significantly higher levels in murine
MSC and detected in both serum free and serum supplemented
human stromal cultures containing MSC. With further validation,
these proteins may provide a useful tool for addressing stromal
culture heterogeneity and further characterizing the therapeutic
potential of MSC.
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